Incidence, Impact and Mechanisms of Perioperative Right VEntricular Dysfunction (IMPRoVE) (IMPRoVE)

April 11, 2023 updated by: Dr Ben Shelley, NHS National Waiting Times Centre Board
A study to see how common right heart failure (right ventricular dysfunction) after major surgery is, and to investigate if right ventricular dysfunction causes worse patient outcomes after surgery.

Study Overview

Detailed Description

Heart attacks are relatively rare around the time of surgery, however by measuring blood markers of heart injury, recent research has revealed that heart injury which otherwise may not be immediately obvious is common. Whilst this type of heart injury appears to be strongly linked to patient outcomes (complications, recovery and survival), the causes and potential treatments for it are not well understood.

Our research group has specialist knowledge about the right-hand side of the heart (right-heart) - the side that pumps blood through the lungs - which is less commonly considered or studied around the time of surgery. We have shown in previous studies using magnetic resonance imaging (MRI) scans (specialised whole-body scans which use a magnet rather than X-rays), evidence of right-heart function deteriorating after surgery. We want to test the idea that some of the blood marker evidence of heart injury reflects injury to the right-heart and more importantly that we can protect the right-heart around the time of surgery, reducing injury and improving patient outcomes.

We will examine these questions in the following ways:

  1. With patients' permission, we will perform detailed ultrasound scans of the heart (echocardiography), and blood measurement of injury markers in 175 patients undergoing different types of major surgery. This will allow us to assess how common heart injury is (visible on scans of both sides of the heart), whether it makes any difference to a patient's outcome and whether it explains the changes seen in blood markers.
  2. We will ask 50 of these patients to undergo MRI scans of the heart pre- and post-operatively to allow us to identify evidence of injury resulting from heart inflammation around the time of surgery. Inflammation is common following surgery and occurs throughout a patient's body - we believe heart inflammation may be responsible for postoperative heart injury.
  3. In 10 of these patients, we will seek to obtain blood samples from vessels flowing into the heart (easily obtained from a simple blood sample) and from veins flowing out of the heart, obtained by passing a fine tube into the heart via blood vessels in a patient's neck under X-ray guidance. This will allow us to examine what happens to immune cells as they pass through the heart (i.e., are they activated by heart inflammation?) and better understand the meaning of the changes seen on MRI scans.

This study will give us a better understanding of which patients are likely to suffer heart injury around the time of surgery and how this injury occurs. With this knowledge, future patients could receive personalised treatment plans aimed at preventing injury and improving outcomes. We are not testing any new treatments in this study.

Study Type

Observational

Enrollment (Anticipated)

175

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Clydebank, United Kingdom
        • Golden Jubilee National Hospital
        • Contact:
          • Ben Shelley
          • Phone Number: 4293 0141 9515000
        • Principal Investigator:
          • Ben Shelley
      • Glasgow, United Kingdom, G4 0SF
        • Glasgow Royal Infirmary
        • Contact:
          • Rachel Kearns
          • Phone Number: 0141 211 4000
        • Principal Investigator:
          • Rachel Kearns
        • Principal Investigator:
          • Sonya McKinlay
      • Glasgow, United Kingdom, G51 4TF
        • Queen Elizabeth University Hospital
        • Contact:
          • Malcolm Watson
        • Principal Investigator:
          • Malcolm Watson
        • Sub-Investigator:
          • Indran Raju

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

175 patients of 18 years or older undergoing major non-cardiac surgery in the West of Scotland. Patients will be recruited from the Golden Jubilee National Hospital, Queen Elizabeth University Hospital, and Glasgow Royal Infirmary.

Description

Main echocardiography study

Inclusion Criteria:

  1. Provision of informed consent
  2. Age >18 years
  3. Planned elective primary hip or knee joint replacement under spinal anaesthesia, major colorectal, major vascular surgery or surgery requiring one lung ventilation with or without lung resection

Exclusion Criteria:

  1. Pregnancy
  2. On-going participation in any investigational research which could undermine the scientific basis of the study
  3. Previous major surgery within three months prior to recruitment
  4. Previous participation in the IMPRoVE study at any time
  5. Inadequate comprehension of English resulting in inability to comply with instructions while undergoing investigations required for main study and sub-studies.

Additional exclusion criteria applicable to the T1 CMR sub-study includes:

  1. Atrial fibrillation at baseline
  2. Contraindication to cardiac magnetic resonance imaging (metal work in body etc)
  3. Contraindication to IV Gadolinium: acute or chronic renal failure, allergy to contrast

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Thoracic surgery cohort
35 patients undergoing thoracic surgery with lung resection and one lung ventilation under primarily general anaesthesia.
Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
10 patients from the thoracic surgical group will undergo right heart catheterisation and coronary sinus blood sampling.
Upper gastrointestinal surgery cohort
35 patients undergoing upper gastrointestinal surgery with one lung ventilation under primarily general anaesthesia.
Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
Colorectal surgery cohort
35 patients undergoing elective colorectal surgery under primarily general anaesthesia.
Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
Vascular surgery cohort
35 patients undergoing elective open abdominal aortic surgery under primarily general anaesthesia.
Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
Orthopaedic surgery cohort
35 patients undergoing elective primary hip or knee arthroplasty under spinal anaesthesia +/- sedation.
Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of postoperative Right ventricular dysfunction (RVD)
Time Frame: Echocardiography performed preoperatively and at day 2-4 postoperatively to measure change in RV function

RVD diagnosed by transthoracic echocardiography, defined as:

  • 2D-speckle tracking derived RV free wall peak longitudinal strain (FWLS) less negative than -20%.
  • Or, (where not available) two of Tricuspid Annular Plane Systolic Excursion (TAPSE) <16mm, S' Wave velocity at the tricuspid annulus <10cm/s or tissue doppler RV index of myocardial performance >0.55
Echocardiography performed preoperatively and at day 2-4 postoperatively to measure change in RV function
Days alive and at home at 30 days postoperatively (DAH30)
Time Frame: Day 30 postoperatively
DAH30 is a continuous number between 0 and 30 which reflects, out of the 30 days following surgery, the total number of those days that a patient spends alive and at home. If a patient dies within those 30 days, their value is set to 0. Data for DAH30 will be obtained by follow-up phone calls following the 30th postoperative day.
Day 30 postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of postoperative left ventricular dysfunction (LVD)
Time Frame: Echocardiography performed preoperatively and at day 2-4 postoperatively to measure change in LV function
LVD classified as mild, moderately or severely impaired, defined by 2D-echocardiography derived biplane LV ejection fraction and the presence of wall motion abnormalities.
Echocardiography performed preoperatively and at day 2-4 postoperatively to measure change in LV function
Cardiac biomarkers
Time Frame: BNP and troponin measured preoperatively, on postoperative days 1 and 2 and on day of postoperative echocardiography (occurring on postoperative days 2-4).
Natriuretic peptides and high sensitivity troponin will be measured pre- and postoperatively.
BNP and troponin measured preoperatively, on postoperative days 1 and 2 and on day of postoperative echocardiography (occurring on postoperative days 2-4).
Cardiovascular complications
Time Frame: Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
Incidence of myocardial infarction, cardiac death, non-fatal cardiac arrest, coronary revascularisation, pulmonary embolus, deep-veined thrombosis, or new onset atrial fibrillation, and major adverse cardiac events
Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
Renal outcomes
Time Frame: Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
Kidney Disease Improving Global Outcome (KDIGO) classification of Acute Kidney Injury (AKI).
Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
Pulmonary outcomes
Time Frame: Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
Atelectasis, pneumonia, acute respiratory distress syndrome or pulmonary aspiration
Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
Infection Outcomes
Time Frame: Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
Fever and clinical suspicion of infection
Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
Neurological outcomes
Time Frame: Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
Delirium and stroke
Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
Sequential Organ Failure Assessment (SOFA) Score
Time Frame: Postoperative day 1,2, day of postoperative echocardiography in all patients. In patients admitted to HDU/ICU, SOFA score will be collected from postoperative day 0-7.
Score 0-24, where higher scores are a worse outcome.
Postoperative day 1,2, day of postoperative echocardiography in all patients. In patients admitted to HDU/ICU, SOFA score will be collected from postoperative day 0-7.
Fifteen-point Quality of Recovery Score (QoR-15)
Time Frame: Pre-operatively and day of postoperative echocardiography (day 2-4 postoperatively).
Fifteen questions assessing the quality of a patients recovery, each question is scored 0-10 with higher scores indicating a worse outcome.
Pre-operatively and day of postoperative echocardiography (day 2-4 postoperatively).
World Health Organisation Disability Assessment Schedule 2.0 (WHODAS 2.0)
Time Frame: Preoperatively, and at day 30, day 90, and one year postoperatively.
WHODAS 2.0 is a self administered questionnaire that assesses a patient's health and disability. Twelve questions are scored 0-4, where a higher score indicates a worse outcome.
Preoperatively, and at day 30, day 90, and one year postoperatively.
EuroQoL Dimension Health Related Quality of Life Questionnaire (EQ-5D-5L)
Time Frame: Preoperatively, and at day 30, day 90, and one year postoperatively.
EQ-5D-5L is a self administered questionnaire that assesses 5 dimensions of a patient's quality of life. Each dimension is scored 1-5, where a higher score indicates a worse outcome.
Preoperatively, and at day 30, day 90, and one year postoperatively.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ben Shelley, National Waiting Times Centre Board

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

April 1, 2023

Primary Completion (Anticipated)

April 1, 2026

Study Completion (Anticipated)

April 1, 2026

Study Registration Dates

First Submitted

March 27, 2023

First Submitted That Met QC Criteria

April 11, 2023

First Posted (Actual)

April 25, 2023

Study Record Updates

Last Update Posted (Actual)

April 25, 2023

Last Update Submitted That Met QC Criteria

April 11, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Right Ventricular Dysfunction

Clinical Trials on Echocardiography

3
Subscribe